Search Results for "Pregnancy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Pregnancy. Results 251 to 260 of 981 total matches.

Perampanel (Fycompa) for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014  (Issue 1435)
; it is classified as a schedule III controlled substance. Pregnancy – Perampanel is classified as category C ...
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are often initially approved by the FDA as adjunctive treatment for partial seizures.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):9-10 |  Show IntroductionHide Introduction

Certolizumab Pegol (Cimzia) and Ustekinumab (Stelara) for Psoriatic Arthritis

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2014  (Issue 1435)
for tuberculosis is recommended before treatment. Pregnancy – All of the TNF inhibitors and ustekinumab ...
Certolizumab pegol (Cimzia – UCB), a tumor necrosis factor (TNF) inhibitor previously approved for treatment of Crohn's disease and rheumatoid arthritis, and ustekinumab (Stelara – Janssen), a human interleukin-12 and -23 antagonist previously approved for treatment of moderate-to-severe plaque psoriasis, have now been approved by the FDA for treatment of active psoriatic arthritis.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):10-2 |  Show IntroductionHide Introduction

Extended-Release Oxycodone and Acetaminophen (Xartemis XR)

   
The Medical Letter on Drugs and Therapeutics • Jul 21, 2014  (Issue 1447)
studies) for use during pregnancy. Prolonged use of opioids during pregnancy can result in neonatal ...
The FDA has approved a fixed-dose extended-release formulation of oxycodone and acetaminophen (Xartemis XR – Mallinckrodt) for oral treatment of acute pain severe enough to require an opioid. Oxycodone is available in the US as a single entity in oral immediate-release (Oxecta, and others) and extendedrelease (OxyContin) formulations. Immediate-release oxycodone is also available in combination with aspirin (Percodan, and others), acetaminophen (Percocet, and others), or ibuprofen (see Table 1).
Med Lett Drugs Ther. 2014 Jul 21;56(1447):59-61 |  Show IntroductionHide Introduction

Ferric Citrate (Auryxia) for Hyperphosphatemia

   
The Medical Letter on Drugs and Therapeutics • Dec 07, 2015  (Issue 1483)
. PREGNANCY — Ferric citrate is classified as category B (no adequate studies in animals or women; risk ...
The FDA has approved ferric citrate (Auryxia – Keryx), an oral phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the second iron-based phosphate binder to be approved in the US, and the first that causes significant systemic absorption of iron. Auryxia is not FDA-approved for treatment of iron deficiency anemia.
Med Lett Drugs Ther. 2015 Dec 7;57(1483):166-7 |  Show IntroductionHide Introduction

A New Abuse-Deterrent Opioid - Xtampza ER

   
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016  (Issue 1497)
with Xtampza ER. PREGNANCY — As with other opioid analgesics, prolonged use of Xtampza ER during pregnancy ...
The FDA has approved Xtampza ER (Collegium), a new extended-release, abuse-deterrent capsule formulation of oxycodone, for management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Med Lett Drugs Ther. 2016 Jun 20;58(1497):77-8 |  Show IntroductionHide Introduction

L-Glutamine (Endari) for Sickle Cell Disease

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018  (Issue 1539)
(12% vs 8%). PREGNANCY AND LACTATION — No data are available on the use of Endari during pregnancy ...
The FDA has approved an oral powder formulation of the amino acid L-glutamine (Endari – Emmaus) to reduce the acute complications of sickle cell disease in patients ≥5 years old. Endari is only the second drug to be approved for use in sickle cell disease; the antimetabolite hydroxyurea (Droxia) was approved 20 years ago. L-glutamine oral powder is also available by prescription as NutreStore for treatment of short bowel syndrome and over the counter as a dietary supplement.
Med Lett Drugs Ther. 2018 Jan 29;60(1539):21-2 |  Show IntroductionHide Introduction

Brexanolone (Zulresso) for Postpartum Depression

   
The Medical Letter on Drugs and Therapeutics • May 06, 2019  (Issue 1571)
allopregnanolone, the major metabolite of progesterone. Allopregnanolone levels rise during pregnancy, peak ...
The FDA has approved the GABAA receptor modulator brexanolone (Zulresso – Sage Therapeutics) for IV treatment of postpartum depression (PPD). Brexanolone is the first drug to be approved by the FDA for this indication.
Med Lett Drugs Ther. 2019 May 6;61(1571):68-70 |  Show IntroductionHide Introduction

FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021  (Issue 1615)
reaction to any component of the vaccine.3 PREGNANCY AND LACTATION — Pregnant women with COVID-19 ...
The FDA has issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech mRNA-based vaccine for prevention of COVID-19 in persons ≥16 years old.
Med Lett Drugs Ther. 2021 Jan 11;63(1615):1-2 |  Show IntroductionHide Introduction

FDA Authorizes Moderna COVID-19 Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021  (Issue 1616)
after vaccination.4 PREGNANCY AND LACTATION — Pregnant women with COVID-19 are at increased risk ...
On December 18, 2020, the FDA issued an Emergency Use Authorization (EUA) for the Moderna mRNA-based vaccine for prevention of COVID-19 in persons ≥18 years old. The Pfizer-BioNTech mRNA-based vaccine received an FDA EUA for the same indication in persons ≥16 years old on December 11, 2020.
Med Lett Drugs Ther. 2021 Jan 25;63(1616):9-10 |  Show IntroductionHide Introduction

Maribavir (Livtencity) for Cytomegalovirus Infection (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
. PREGNANCY AND LACTATION — No data are available on the use of maribavir during pregnancy. In a study ...
Maribavir (Livtencity – Takeda), an oral cytomegalovirus (CMV) pUL97 kinase inhibitor, has been approved by the FDA for treatment of post-transplant CMV infection refractory to standard antiviral therapy in patients ≥12 years old who weigh at least 35 kg.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e193-4 |  Show IntroductionHide Introduction